Table 1.
Humanized monoclonal antibodies: Antigenic, neutralization, and virion binding properties
| Chimeric mAb | mAb Isotype | PRNT50 (μg/ml) a | Virion binding (Kd-app, nM) b | ||
|---|---|---|---|---|---|
| Mouse-human | |||||
| DV1-E50 (D-III) c | DENV1 | DENV2 | DENV1 | DENV2 | |
| DV1-E50-1 | IgG1 | 0.18 | - | 11.9 | - |
| DV1-E50-2 | IgG2 | 0.95 | - | 19.0 | - |
| DV1-E50-3 | IgG3 | 0.02 | - | 8.1 | - |
| DV1-E50-4 | IgG4 | 0.10 | - | 15.4 | - |
| WNV-E60 (D-II) | |||||
| WNV-E60-1 | IgG1 | 0.39 | 0.03 | 20.8 | 9.1 |
| WNV-E60-2 | IgG2 | 1.52 | 0.30 | 19.4 | 8.6 |
| WNV-E60-3 | IgG3 | 0.17 | 0.01 | 7.7 | 7.2 |
| WNV-E60-4 | IgG4 | 0.38 | 0.04 | 9.3 | 7.2 |
| Chimpanzee-human | |||||
| 1A5 (D-II) | |||||
| 1A5 WT | IgG1 | - | 0.84 | - | 21.0 |
| 1A5 ΔA | IgG4 | - | 0.89 | - | 18.4 |
| 1A5 ΔB | IgG2 | - | 0.83 | - | 46.7 |
| 1A5 ΔD | IgG9X d | - | 0.82 | - | 22.5 |
a
50% Plaque reduction neutralization (PRNT50) end-point titers in Vero cells calculated by probit analysis.
b
Values represent the apparent Kd (Kd-app) calculated for the mAb concentration that produced 50% of maximum virion binding determined by ELISA.
c
DENV envelope E domain (D) specificity.
d
9-amino acid Fc deletion into the 1A5 Fc CH2 domain.